Anti-prion activity found in beetle grub hemolymph of Trypoxulus dichotomus septentrionalis

Taichi Hamanaka, Keiko Nishizawa, Yuji Sakasegawa, Hiroshi Kurahashi 1, Ayumi Oguma, Kenta Teruya, Katsumi Doh-ura*

Department of Neurochemistry, Tohoku University Graduate School of Medicine, 2-1 Seiryocho, Sendai 980-8575, Japan

ABSTRACT

No remedies for prion disease have been established, and the conversion of normal to abnormal prion protein, a key event in prion disease, is still unclear. Here we found that substances in beetle grub hemolymph, after they were browned by aging for a month or heating for hours, reduced abnormal prion protein (PrP) levels in RML prion-infected cells. Active anti-prion components in the hemolymph were resistant to protease treatment and had molecular weights larger than 100 kDa. Aminoguanidine treatment of the hemolymph abolished its anti-prion activity, suggesting that Maillard reaction products are enrolled in the activity against the RML prion. However, levels of abnormal PrP in RML prion-infected cells were not decreased by incubation with the Maillard reaction products formed by amino acids or bovine serum albumin. The anti-prion components in the hemolymph modified neither cellular or cell-surface PrP levels nor lipid raft or autophagosome levels. The anti-prion activity was not observed in cells infected with 22 L prion or Fukuoka-1 prion, suggesting the anti-prion action is prion strain-dependent. Although the active components of the hemolymph need to be further evaluated, the present findings imply that certain specific chemical structures in the hemolymph, but not chemical structures common to all Maillard reaction products, are involved in RML prion formation or turnover, without modifying normal PrP expression. The anti-prion components in the hemolymph are a new tool for elucidating strain-dependent prion biology.

1. Introduction

Prion diseases, also called transmissible spongiform encephalopathies, are progressive, fatal neurodegenerative illness. They include Creutzfeldt-Jakob disease in humans and scrapie, bovine spongiform encephalopathy, and chronic wasting disease in animals. These diseases are characterized by the accumulation of abnormal prion protein (abnormal PrP), which is a main component of the prion that is derived from the normal prion protein (PrPc) through a conformational transformation [1]. Abnormal PrP molecules form insoluble protein polymers, which have protease-resistant cores (PrPres). Both the conversion of PrPc to abnormal PrP and the turnover of abnormal PrP are key events in prion diseases but are still unclear.

As for remedies for these diseases, dozens of compounds or substances have been reported to either inhibit prion formation in prion-infected culture cells or to prolong the incubation period in prion-infected animals [2–4]. Some remedies are effective in a prion-strain dependent fashion [5–8], but the mechanism underlying prion strain-dependent efficacy remains unclear. Although a few anti-prion compounds have been tested in clinical trials against human prion diseases, no sufficiently beneficial effects have ever been reported [9–13].

To obtain clues for the development of remedies as well as to explore the mechanism of the enigmatic PrP conversion, we searched for compounds or substances that modify abnormal PrP formation in prion-infected cells. In earlier studies [14,15], medicinal compounds or natural products approved by the United States Food and Drug Administration had been extensively screened for anti-prion activity. Therefore, we focused on untouched materials obtained from natural sources. We had previously reported anti-prion substances extracted from natural sources, including fucoidan and protein-bound polysaccharide K [16,17]. Insects are under-cultivated natural resources, which exist abundantly in both number and variety. It may be possible to discover new insect-derived substances that are useful either for exploring the PrP conversion mechanism, or for developing the
treatment, or prophylaxis of the illness. In fact, anticancer, antiviral, and antimicrobial compounds are found in insect extracts [18–21].

Here we examined insect larva-derived hemolymph, using prion-infected cells. We found that beetle grub hemolymph inhibited abnormal PrP formation in prion-infected cells when the hemolymph was browned by aging or heating. We then studied the mechanism by which the browned hemolymph enacted its anti-prion properties. The Maillard reaction products, also called advanced glycation end products (AGEs), in the browned hemolymph were suggested to contain the active, anti-prion components. These substances are a new type of probe for identifying the prion strain-dependent formation of abnormal PrP.

2. Materials and methods

2.1. Samples and reagents

We obtained grubs of the Japanese horned beetle, Trypoxylus dichotomus septentrionalis, at the third instar larval stage, from a local insect shop. Hemolymph from these grubs was obtained as previously described [22,23] with minor modification. Briefly, phosphate buffer saline (PBS, 100 μL) was injected into the body of grubs, and the grubs were reared in leaf mold for 5 h. After surface sterilization and anesthesia on an ice pack, bleeding was done through the amputated prolegs. Hemolymph was collected into tubes on ice and immediately heated at 95 °C for 5 min. The hemolymph fluids were subsequently centrifuged at 20,000 × g for 10 min at 4 °C. The supernatant from this step was the source of the hemolymph samples used in the study. The hemolymph samples were stored at −80 °C, after addition of 20 μg/mL aprotenin (Roche, Penzberg, Germany), until use.

Aminoguanidine, glucose, amino acids, and bovine serum albumin (BSA) were purchased from Wako Pure Chemical Industries (Osaka, Japan). Maillard reaction products of amino acids or BSA were purchased from Wako Pure Chemical Industries (Osaka, Japan). Aminoguanidine (AG), glucose, amino acids, and bovine serum albumin (BSA) were purchased from Wako Pure Chemical Industries (Osaka, Japan). All the findings described above imply the involvement of the Maillard reaction in the production of active anti-prion components in the hemolymph samples. Therefore, we examined whether the Maillard reaction inhibitor aminoguanidine abolished the anti-prion activity of the hemolymph samples, by heating a mixture of hemolymph and aminoguanidine at 70 °C for 17 h and subsequently adding the mixture to ScN2a cells. The presence of Maillard reaction products was confirmed by immunoblotting with 6D12 monoclonal antibody, which specifically detects N(6)-carboxymethyl lysine in Maillard reaction products. As shown in Fig. 2A, no N(6)-carboxymethyl lysine signals were detected in hemolymph samples prepared in the presence of aminoguanidine. Coincidently, anti-prion activity was abolished in hemolymph samples prepared in the presence of aminoguanidine (Fig. 2B). The results indicate that the Maillard reaction process is necessary for the production of anti-prion components in hemolymph samples.

3. Results

3.1. Anti-prion activity of beetle grub hemolymph

We examined whether beetle grub hemolymph of Trypoxylus dichotomus septentrionalis has anti-prion activity in RML prion-infected cells. Cells were incubated with the culture medium containing the hemolymph samples for three days. PrPres levels were subsequently assayed by immunoblotting. Beetle grub hemolymph samples were transparent immediately after collection and heat inactivation, but they gradually changed to a tan color while stored at 4 °C. The non-aged hemolymph samples did not inhibit the formation of abnormal PrP in ScN2a cells. However, the hemolymph samples that had become brown after storage for 1 month at 4 °C inhibited the formation of abnormal PrP in ScN2a cells. The anti-prion activity was never observed in hemolymph samples that had been stored for 2 months at 4 °C (Fig. 1A). These results indicate that beetle grub hemolymph samples contain anti-prion activity that was gained during aging for one month at 4 °C, but was lost during an additional month of storage. To shorten the aging period, the hemolymph samples were heated at 37 °C or 70 °C for 17 h. These heat treatments caused the hemolymph samples to turn brown and to inhibit the formation of abnormal PrP in ScN2a cells (Fig. 1B). These results suggest that temperature is one of the factors that facilitate the production of anti-prion components in hemolymph samples. Anti-prion activity was observed in hemolymph samples heated at 70 °C for only 3 h; the anti-prion activity was coincident with the formation of brown color in the hemolymph samples (Fig. 1C). The anti-prion activity was maintained in samples treated with protease (Fig. 1D). The molecular mass of the anti-prion components in the hemolymph samples was examined by using centrifugal ultrafiltration devices. The anti-prion components were found in the retentate of a filter with a 100 kDa cut-off, the anti-prion activity was not observed in the filtrates of any of the four types of filters (Fig. 1E).

3.2. Characterization of anti-prion components in beetle grub hemolymph

All the findings described above imply the involvement of the Maillard reaction in the production of active anti-prion components in the hemolymph samples. Therefore, we examined whether the Maillard reaction inhibitor aminoguanidine abolished the anti-prion activity of the hemolymph samples, by heating a mixture of hemolymph and aminoguanidine at 70 °C for 17 h and subsequently adding the mixture to ScN2a cells. The presence of Maillard reaction products was confirmed by immunoblotting with 6D12 monoclonal antibody, which specifically detects N(6)-carboxymethyl lysine in Maillard reaction products. As shown in Fig. 2A, no N(6)-carboxymethyl lysine signals were detected in hemolymph samples prepared in the presence of aminoguanidine. Coincidently, anti-prion activity was abolished in hemolymph samples prepared in the presence of aminoguanidine (Fig. 2B). The results indicate that the Maillard reaction process is necessary for the production of anti-prion components in hemolymph samples.

Meanwhile, we examined whether other Maillard reaction products exert anti-prion activity in ScN2a cells. We investigated Maillard reaction products prepared by incubation of amino acids or BSA with glucose at 70 °C for 17 h. The results demonstrate that the levels of abnormal PrP formed in ScN2a cells were not reduced by any of these samples. Rather, the levels of abnormal PrP increased obviously in ScN2a cells treated with samples prepared from lysine or a lysine-containing amino acid mixture (Fig. 2C, Glucose (+)). This increase in PrPres levels was abolished when the samples were prepared in the presence of aminoguanidine (Fig. 2C, Glucose (+) and AG (+)). These results suggest that
certain specific components in the hemolymph, rather than the common structures of Maillard reaction products, are needed for anti-prion activity against the RML prion.

3.3. Effects on PrPc expression and other prion strains

We examined the influence of anti-prion hemolymph components on PrPc expression. We found that the browned hemolymph samples, prepared by heating the hemolymph at 70 °C for 17 h, modified neither the total cellular PrPc levels (Fig. 3A) nor the cell surface PrPc levels in N2a cells (Fig. 3B). The lipid raft microdomain of the cell membrane, which is reportedly one of the possible sites of PrP conversion or of interaction between PrPc and abnormal PrP [27–31] was also examined. The cholera toxin B-binding lipid raft levels were not modified in N2a cells treated with the browned hemolymph samples (Fig. 3B). We examined the anti-prion activity of the browned hemolymph samples in two other cells infected with distinct prion strains: N167 cells infected with 22 L prion and F3 cells infected with Fukuoka-1 prion. The browned hemolymph samples showed no anti-prion activity in these two cell cultures (Fig. 3C). These data suggest that the browned hemolymph samples exert anti-prion activity in a prion-strain dependent manner without any effects on PrPc expression.

Autophagy has been reported to regulate abnormal PrP clearance [32]. Therefore, we examined whether autophagosome formation is enhanced in ScN2a cells treated with browned hemolymph samples. We found that the browned hemolymph samples did not enhance autophagosome formation in these cells (Fig. 3D). Similarly, compounds such as the tetracycline group compounds [33] and polycationic compounds [34] turn abnormal PrP molecules into less protease-resistant PrP molecules when cell lysates containing abnormal PrP molecules are incubated with these compounds. Therefore, we tested whether browned hemolymph samples modify the protease sensitivity of abnormal PrP.
The results showed that the browned hemolymph samples did not change the protease sensitivity of abnormal PrP molecules and did not modify the stability of PrPc molecules (Fig. 3E).

4. Discussion

In the present study, we found that beetle grub hemolymph of Trypoxylus dichotomus septentrionalis, when it is browned at 4 °C for a month or heated for hours, inhibits abnormal PrP formation in RML prion-infected cells. Anti-prion components in the browned hemolymph were protease resistant and had a molecular weight greater than 100 kDa. Treatment of the hemolymph with aminoguanidine abolished the production of anti-prion activity, which strongly suggests that the anti-prion components are Maillard reaction products. Conversely, Maillard reaction products of amino acids or BSA did not inhibit abnormal PrP formation in RML prion-infected cells. Therefore, although the active components of browned hemolymph need to be further evaluated, certain specific chemical structures in the hemolymph, but not the common structures of Maillard reaction products, are likely to be involved in inhibiting abnormal PrP formation in cells infected with the RML prion.

Although many compounds or biological materials have been reported to inhibit the formation of abnormal PrP in prion-infected cells, this type of Maillard reaction product has never been reported to have anti-prion activity. High-molecular-weight substances, including polycationic polymers [34], polyanionic glycans [35], and the protein-polysaccharide complex substance PSK [17] have potent anti-prion activity in prion-infected cells. However, the anti-prion components in the hemolymph are different from these high-molecular-weight substances. The anti-prion components in the hemolymph exhibit prion-strain dependent efficacy, whereas those high-molecular-weight substances are effective not only in RML prion-infected cells but also in cells infected with other prion strains.

As substances similar to Maillard reaction products, melanin, which is similarly brown-colored and of high molecular weight, is considered because melanin is easily produced even in collected...
hemolymph fluids by endogenous phenoloxidase enzymes. However, it is unlikely that melanin was produced in the hemolymph samples we used, because they were collected in an ice cold condition and were immediately heated at 95°C to inactivate phenoloxidase enzymes. In fact, the phenoloxidase enzymes in fly larvae hemolymph are reportedly inactivated by heating at 50°C or higher [36].

Regarding the mechanism of the action of the anti-prion components of the browned hemolymph in prion-infected cells, they had no effect on PrPc expression and localization; total cellular and cell surface PrPc levels were not modified; and cell membrane lipid raft microdomain levels were unchanged. In addition, the anti-prion components of the browned hemolymph did not modify autophagosome levels, and they were active in a prion strain-dependent manner. Considering all these together, these results suggest that the anti-prion components of the browned hemolymph reduce abnormal PrP levels by directly modifying abnormal PrP formation or turnover. We previously experienced similar results with amyloidophilic compounds such as compound B, BSB, and styrylbenzoazole derivatives [37]. We speculate that the prion strain-dependent efficacy of these compounds is attributable to strain-specific structure, biosynthesis, or turnover of abnormal PrP molecules. However, none of these mechanisms of prion strain-dependency have previously been reported. The present findings of a new class of anti-prion materials might provide a clue to understanding the mechanisms of strain-dependent anti-prion activity.

There are a few reports describing the roles of Maillard reaction products or AGEs in prion biology or prion disease pathogenesis [38–40]. Choi and colleagues found that one or more lysine residues and one arginine residue of abnormal PrP are specifically modified with AGEs [38]. They suggest the Maillard reaction is responsible for one of the post-translational modifications of abnormal PrP, and that it might facilitate protection of abnormal PrP molecules against cellular degradation. Sasaki and colleagues found that both PrP-positive granules and AGE- or AGE receptor-immunopositive granules are colocalized in the astrocytes of human brains with prion disease, and they proposed an AGE receptor-mediated PrP degradation pathway in prion-infected brains [39]. Taken together, these results suggest that the Maillard reaction plays an important role in the biosynthesis and turnover of abnormal PrP. Meanwhile, the findings of this study suggest that
certain Maillard reaction products inhibit abnormal PrP formation in prion-infected cells. Thus, although their chemical structure needs to be further elucidated, the anti-prion components of the browned hemolymph of beetle grubs are a new tool for resolving an enigma of prion formation and turnover. These findings may also provide a clue to as to why some compounds are effective in a prion strain-dependent manner.

Conflict of interest

None.

Acknowledgements

We thank Yuka Fujisawa for technical assistance. This research was supported by Grants-in-Aid for Scientific Research (22390172) from the Ministry of Education, Culture, Sports, Science and Technology, Japan; a grant for Research on Measures for Intractable Diseases (H22-ippan-009) from the Ministry of Health, Labour, and Welfare of Japan; and a grant (06-43) from the National Institute of Biomedical Innovation, Osaka, Japan.

Appendix A. Supplementary material

Supplementary data associated with this article can be found in the online version at http://dx.doi.org/10.1016/j.bbrep.2015.07.009.

References

1. S.B. Prusiner, Prions, Proc. Natl. Acad. Sci. USA 95 (1998) 13363–13383.
2. C.R. Trevitt, J. Collinge, A systematic review of prion therapies in experimental models, Brain 129 (2006) 2241–2265.
3. V.L. Sim, Prion disease: chemotherapeutic strategies, Infect. Disord. Drug Targets 12 (2012) 144–160.
4. K. Teruya, K. Doh-ura, Amyloid-binding compounds and their anti-prion potency, Curr. Top. Med. Chem. 13 (2013) 2522–2532.
5. K. Ishikawa, K. Doh-ura, Y. Kudo, et al., Amyloid imaging probes are useful for detection of prion plaques and treatment of transmissible spongiform encephalopathies, J. Gen. Virol. 85 (2004) 1785–1790.
6. K. Ishikawa, Y. Kudo, N. Nishida, et al., Styrlybenzoazole derivatives for imaging of prion plaques and treatment of transmissible spongiform encephalopathies, J. Neurochem. 99 (2006) 138–205.
7. Y. Kawasaki, K. Kawagoe, C.J. Chen, et al., Orally administered amyloidophic compound is effective in prolonging the incubation periods of animals cerebroselectively infected with prion strains, J. Virol. 68 (2001) 12189–12198.
8. D.B. Berry, D. Lu, M. Geva, et al., Drug resistance confounding prion therapeutics, Proc. Natl. Acad. Sci. USA 110 (2013) E4160–E4169.
9. M. Otto, L. Cepek, P. Ratcliffe, et al., Amyloidophilic compounds and their anti-prion properties, J. Virol. 61 (2007) 12889–12898.
10. D.B. Berry, D. Lu, M. Geva, et al., Drug resistance confounding prion therapeutics, Proc. Natl. Acad. Sci. USA 110 (2013) E4160–E4169.
11. M. Otto, L. Cepek, P. Ratcliffe, et al., Amyloidophilic compounds and their anti-prion properties, J. Virol. 61 (2007) 12889–12898.
12. M.D. Geschwind, A.L. Kuo, K.S. Wong, et al., Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease, Neurology 81 (2013) 2015–2023.
13. S. Haik, G. Marcon, A. Mallet, et al., Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial, Lancet Neurol. 13 (2014) 150–158.
14. C. Korth, B.C. May, F.E. Cohen, et al., Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease, Proc. Natl. Acad. Sci. USA 98 (2001) 9836–9841.
15. D.A. Kocisko, G.S. Baron, R. Rubenstein, et al., New inhibitors of scrapie-associated prion formation in a library of 2,000 drugs and natural products, J. Virol. 77 (2003) 10288–10294.
16. K. Doh-Ura, T. Kuge, M. Uomoto, et al., Prophylactic effect of dietary seaweed Fucoidan against enteral prion infection, Antimicrob. Agents Chemother. 51 (2007) 2274–2277.
17. T. Hanamana, Y. Sakasegawa, A. Ohmoto, et al., Anti-prion activity of protein-bound polysaccharide K in prion-infected cells and animals, Biochem. Biophys. Res. Commun. 405 (2011) 285–290.
18. S. Natori, Function of antimicrobial proteins in insects, Ciba Found. Symp. 186 (1994) 123–132.
19. M. Slocinska, P. Marciniak, G. Rosinski, Insects antiviral and anticancer peptides: new leads for the future? Protein Pept. Lett. 15 (2008) 578–585.
20. R. Ratcliffe, C.B. Scapie, Isolation, Curr. Top. Med. Chem. 13 (2013) 2522–2532.
21. R. Iijima, S. Kurata, S. Natori, Purification, characterization, and cDNA cloning of an antifungal protein from the hemolymph of Sarcophaga peregrina (flesh fly) larvae, J. Biol. Chem. 268 (1993) 12055–12061.
22. A. Miyajima, S. Hara, M. Sugiyama, et al., Isolation and characterization of a new member of the insect defensin family from a beetle, Alloomyrina dichotoma, Biochem. Biophys. Res. Commun. 220 (1996) 526–531.
23. K. Doh-Ura, T. Iwaki, B. Caughey, Lysozyme-tropalin and cytochrome inhibitors inhibit scrapie-associated prion protein accumulation, J. Virol. 74 (2000) 4894–4897.
24. K. Ishizawa, A. Oguma, M. Kawata, et al., Efﬁcacy and mechanism of a glycoside compound inhibiting abnormal prion protein formation in prion-infected cells: implications of interferon and phosphorylation of 4D-interacting protein, J. Virol. 88 (2014) 4039–4095.
25. K. Ikeda, T. Higashi, H. Sano, et al., (epilisin)-(carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modiﬁed with advanced glycation end products of the Maillard reaction, Biochemistry 35 (1996) 8075–8083.
26. A. Taraboulos, M. Scott, A. Semenov, et al., Cholesterol depletion and modification of COOH-terminal targeting sequence of the prion protein inhibit formation of the scrapie isoform, J. Cell Biol. 129 (1995) 121–132.
27. R. Klingensten, S. Lobor, P. Kujala, et al., Tricyclic antidepressants, quinacrine and a novel, synthetic chimera thereof clear prions by destabilizing detergent-resistant membrane compartments, J. Neurochem. 98 (2006) 748–759.
28. S. Gólich, C. Bach, G. Lütkay, et al., Inhibition of cholesterol recycling impairs cellular PrPSc propagation, Cell. Mol. Life Sci. 66 (2009) 3979–3991.
29. C. Bate, M. Tajeby, A. Williams, Glycosylphosphatidylinositol anchor analogues sequester cholesterol and reduce prion formation, J. Biol. Chem. 285 (2010) 22017–22026.
30. A. Rouvinski, S. Karmiel, M. Kounin, et al., Live imaging of prions reveals nascent PrPSc in cell-surface, raft-associated amyloid strings and webs, J. Cell Biol. 204 (2014) 423–441.
31. A. Hesseke, Y. Agubi, H.M. Schatzl, Autophagy, prion infection and their mutual interactions, Curr. Issues Mol. Biol. 12 (2010) 87–97.
32. F. Tagliavini, G. Forloni, L. Colombo, et al., Tetracycline affects abnormal protein aggregation, Rejuvenation Res. 13 (2010) 223.
33. S. Supattapone, J.R. Piro, J.R. Rees, Complex polypeptides: unique prion disaggregating compounds, CNS Neurolog. Disord. Drug Targets 8 (2009) 323–328.
34. B. Caughey, G.J. Raymond, Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells, J. Virol. 67 (1993) 643–650.
35. K. Maruta, T. Hara, T. Tsukamoto, Properties of phenoloxidase purified from larvae of the houkey, B. Fac. Agr. Saga Univ. 67 (1989) 127–139.
36. K. Teruya, K. Kawagoe, T. Kiruma, et al., Amyloidophilic compounds for prion diseases, Infect. Disord. Drug Targets 9 (2009) 15–22.
37. Y.G. Choi, J.J. Kim, J.C. Jeon, et al., Nonenzymatic glycation at the N terminus of pathogenic prion protein in transmissible spongiform encephalopathies, J. Biol. Chem. 279 (2004) 30402–30409.
38. N. Sasaki, M. Takeuchi, H. Chowei, et al., Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques, Neurosci. Lett. 326 (2002) 117–120.
39. G. Panza, C. Dumpitak, E. Birkmann, Influence of the maillard reaction to prion protein aggregation, Rejuvenation Res. 13 (2010) 220–223.